EarningsQ2 2026 Earnings Report
DE:UNH Q2 2026 EPS Results
Actual EPS€5.51
Consensus EPS€4.24
Beat/MissBeat by +€1.27
One Year Ago EPS€3.52
DE:UNH Q2 2026 Revenue Results
Actual Revenue€96.71B
Expected Revenue€95.66B
Beat/MissBeat by +€1.06B
YoY Revenue Growth+0.37%
Earnings Announcement Details
QuarterQ2 2026
Date07/16/2026
TimeBefore Open
Conference CallThursday, July 16, 2026
DE:UNH Upcoming Earnings
UnitedHealth's next earnings date is estimated for October 9, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:UNH Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call reflects a broadly positive tone: strong quarter-to-date financial results (notably double-digit EPS growth and raised guidance), solid operational progress across Optum (AI-led efficiency gains, improved care metrics), and meaningful shareholder returns and balance sheet improvement. However, the company faces notable near-term headwinds—elevated commercial medical cost trends, pressured Medicaid margins, Medicare enrollment declines, and some one-time favorable prior-period development—creating areas of ongoing focus and uncertainty. On balance, the positive developments and upgraded outlook outweigh the challenges, but management emphasizes continued urgency and investment to sustain improvement.Company Guidance
Strong Earnings and Profitability
Adjusted EPS of $6.38 in 2Q26 versus $4.08 in 2Q25, an increase of ~56%; operating earnings of $8.0B, up 55% year-over-year.
Raised Full-Year Guidance
Updated adjusted EPS guidance to $19.50–$20.00 for full-year 2026; increased UnitedHealthcare operating earnings outlook to at least $12B and Optum Health to at least $2.2B.
Improved Medical Care Ratio in Quarter
Reported medical care ratio of 86.7% in 2Q26 vs 89.4% in 2Q25 (improvement of ~270 basis points); includes $860M of net favorable prior period medical development.
Optum Momentum and Operational Wins
All three Optum segments performing in line or ahead of plan; Optum Health showing care improvements (≈10% reduction in hospitalizations in targeted regions; >20% improvement in timely home-health care pilots) and patient experience up ~5% YoY; Optum Health reaches ~90% of U.S. counties and conducts ~2.5M rural home visits.
Optum Rx and Optum Insight Progress
Optum Rx retention in the high-90s and expects >95% of clients on 100% rebate pass-through by end of 2026; Optum Insight AI products (e.g., Value Connect) producing results including a 17% reduction in pharmacy costs and digital prior authorization showing 96% first-pass approval for internal use cases.
Capital Return and Balance Sheet Strength
Operating cash flow ~ $11B (1.9x net income); repurchased $4B of shares YTD (11.4M shares) and now expect at least $5B total repurchases in 2026 (versus prior $2.5B target); dividend increased and $2.1B returned in the quarter; debt-to-capital improved to 41.2% from 44.1% a year ago (≈290 bps improvement).
Execution on Prior Authorization and Access Initiatives
Committed to eliminating 30% of prior authorization volume and nearly two-thirds of pediatric prior authorization requirements by year-end 2026; investing in AI-enabled prior authorization and digital experiences (digital prior auth product processed ~500k prior auths and saved ~69k administrative hours year-to-date for external/internal customers).
DE:UNH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed